NCT06157905Early phase 1Completed
Efficacy and Safety of Oral Tofacitinib in the Treatment of Alopecia Areata
In the register
This trial is not attached to a programme in the register yet. Unattached trials are kept on purpose: they are where new programmes turn up first.
What the registry records
- Status
- Completed
- Declared phase
- Early phase 1
- Sponsor
- Services Institute of Medical Sciences, Pakistan
- Participants (registry)
- 9
- Start
- August 2022
- Primary completion
- February 2023
- Study completion
- August 2023
- Last registry update
- December 2023
- Countries
- Pakistan
Conditions studied: Extensive Alopecia Areata
Interventions: Oral Tofacitinib citrate
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first. A registration proves a sponsor declared a study, not that it is progressing or will succeed. We're not doctors.